Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 302
- Registration Number
- NCT00659841
- Locations
- 🇺🇸
Altana/Nycomed, San Antonio, Texas, United States
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00608218
- Locations
- 🇩🇪
"Nycomed Deutschland GmbH", Würzburg, Germany
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
- Conditions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT00546520
- Locations
- 🇬🇧
"Altana Pharma/Nycomed", London, United Kingdom
Effect of Ciclesonide on Exercise Induced Bronchoconstriction
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2009-10-21
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT00525772
- Locations
- 🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Covis Pharma S.à.r.l.
- Target Recruit Count
- 30
- Registration Number
- NCT00458835
- Locations
- 🇺🇸
ALTANA Pharma, Austin, Texas, United States
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
- Conditions
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1121
- Registration Number
- NCT00404547
- Locations
- 🇨🇦
"Altana Pharma/Nycomed", York, Canada
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 528
- Registration Number
- NCT00392288
- Locations
- 🇲🇽
Sanofi-Aventis, Mexico, Mexico
🇵🇱sanofi-aventis Poland, Warszawa, Poland
🇭🇺Sanofi-Aventis Hungaria, Budapest, Hungary
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1080
- Registration Number
- NCT00384189
- Locations
- 🇺🇦
Altana Pharma/Nycomed, Zaporizhzhya, Ukraine
Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00306163
- Locations
- 🇳🇱
Altana Pharma/Nycomed, RB Groningen, Netherlands
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT00305461
- Locations
- 🇦🇷
Altana Pharma/Nycomed, Tucuman, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.